Exonic
Fall 2025 · Active
Crowdsourcing drug discovery.
Location: San Francisco, US
Founded: 2025
Team size: 3
About
Exonic is building a global network of intelligence to cure all disease.
We are the first drug discovery company open to everyone.
Today drug discovery is siloed - secretive, adversarial institutions in glass towers.
Biological AI is changing the rules. Every day drug discovery becomes more of a computational problem.
Exonic is turning drug discovery into an open, meritocratic tournament.
We are advised by world leaders in bio AI, including the former Head of AI at Ginkgo Bioworks, and the first author of Evo (cover of Science).
All of the best biological AI models are open source. And on Exonic, you can combine them, prompt them, and share your innovative workflows without writing a single line of code.
Using Exonic Studio, we just beat a state-of-the-art benchmark in liver cancer (HepG2) synthetic enhancer design, validated in our wet lab.
The platform just went live - you can start right now.
We are turning the internet into a drug discovery powerhouse.
Founders
Ben BrimacombeFounder
Co-founded Free2Grow, AI voice company at $1.5M+ ARR. Co-led Turnpoint contract ($1.4B revenue aggregator) at Free2Grow. Published AI researcher (EMNLP, 2023). Led machine learning at Long Run Partners, multi-hundred million dollar NYC mortgage bank (employee #9). Ex Numerai, the crowdsourced hedge fund ($500m+ AUM). Columbia Computer Science and Mathematics, 2020.